Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal-F1).

Aims: T-emerge 2 was a randomized, open-label, 24-week trial comparing subcutaneous taspoglutide 10mg weekly (Taspo10), taspoglutide 20mg weekly (Taspo20; titrated after 4weeks of Taspo10), with exenatide 10 mcg BID (Exe; after 4weeks of Exe 5 mcg) in patients inadequately controlled on metformin, a thiazolidinedione, or both. T-emerge 2 showed that once-weekly Taspo provided better glycaemic control than Exe. This report focuses on a subset of T-emerge 2 participants undergoing a standardized liquid meal comparing Taspo to Exe, which has been previously shown to lower postprandial glucose. Methods: Meal tolerance tests (MTT) were performed at baseline and at week 24 in a subset of Taspo10, Taspo20 and Exe patients (n=42, 39 and 67, respectively). Blood samples for glucose, insulin, glucagon and C-peptide were obtained before and after (30, 60, 90, 120 and 180min) ingestion of a standardized liquid meal. Results: The 2-h postprandial, mean 0-3h and iAUC0-3h glucose during the MTT was reduced to a similar extent in all groups and the time profile of the postprandial glucose showed a similar pattern. Taspo10 and Taspo20, but not Exe, significantly increased insulin from baseline (both mean and iAUC0-3h). Although changes from baseline in C-peptide were not significant within any treatment group, the mean change from baseline (both mean 0-3h and iAUC0-3h) was significantly increased in Taspo10 vs. Exe. Mean glucagon showed significant decreases in all groups. Conclusion: Taspoglutide and Exe improved postprandial glucose tolerance to a similar extent but possibly with different intimate mechanisms